FDA to assess whether saxagliptin raises heart risks

02/12/2014 | Reuters

The FDA is set to evaluate potential heart risks linked to the diabetes drug saxagliptin by AstraZeneca. The FDA will consider the issue after the drugmaker submits data from clinical trials, expected by early March. The investigation follows publication of research in the New England Journal of Medicine that revealed saxagliptin-treated patients showed a slight increase in heart failure admissions.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ